AU2023282272B2 — Microcrystalline diketopiperazine compositions and methods
Assigned to Mannkind Corp · Expires 2025-04-24 · 1y expired
What this patent protects
Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and…
USPTO Abstract
Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray drying a solution containing the components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and/or small organic molecules.
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.